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ABSTRACT
In addition to genetic mutations, epigenetic revision plays a major role in the 
development and progression of cancer; specifically, inappropriate DNA methylation 
or demethylation of CpG residues may alter the expression of genes that promote 
tumorigenesis. We hypothesize that DNA repair, specifically the repair of DNA double 
strand breaks (DSB) by Non-Homologous End Joining (NHEJ) may play a role in this 
process. Using a GFP reporter system inserted into the genome of HeLa cells, we 
are able to induce targeted DNA damage that enables the cells, after successfully 
undergoing NHEJ repair, to express WT GFP. These GFP+ cells were segregated into 
two expression classes, one with robust expression (Bright) and the other with reduced 
expression (Dim). Using a DNA hypomethylating drug (AzadC) we demonstrated that 
the different GFP expression levels was due to differential methylation statuses of 
CpGs in regions on either side of the break site. Deep sequencing analysis of this area 
in sorted Bright and Dim populations revealed a collection of different epi-alleles that 
display patterns of DNA methylation following repair by NHEJ. These patterns differ 
between Bright and Dim cells which are hypo- and hypermethylated, respectively, and 
between the post-repair populations and the original, uncut cells. These data suggest 
that NHEJ repair facilitates a rewrite of the methylation landscape in repaired genes, 
elucidating a potential source for the altered methylation patterns seen in cancer cells, 
and understanding the mechanism by which this occurs could provide new therapeutic 
targets for preventing this process from contributing to tumorigenesis.
INTRODUCTION
DNA may be methylated on cytosine residues 
of CpG islands by the catalytic activity of DNA 
methyltransferases (DNMTs). DNA methylation may 
be classified as either invariant and stable (sex-specific 
imprinting) or metastable. In somatic cells, DNA 
methylation is metastable and changes with age [1], diet 
[2, 3], environment [4], disease [5–8], or other external 
or intrinsic events [9]. In this work, we are examining 
somatic, metastable DNA methylation. This epigenetic 
modification is usually associated with gene silencing 
[10, 11] as it interferes with transcription machinery and 
is recognized by proteins that recruit histone modifiers 
to condense chromatin, an action which blocks the 
accessibility of transcription machinery to the affected 
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genes [12–14]. Under normal conditions, epigenetic 
modifications serve to modulate gene expression during 
embryonic development [15] and genomic imprinting 
[16], differentiation [17], or in response to stimuli [18]; 
however unscheduled changes can cause inappropriate 
gene silencing of tumor suppressor genes or activation of 
oncogenes, a phenomenon that is seen in various types of 
cancer cells [10, 19–21].
In order to pass the G2 checkpoint and enter mitosis, 
cells must repair any DNA damages that have occurred. 
Double stranded breaks in DNA (DSBs), in which breaks 
occur in both strands of the DNA double helix in close 
proximity to one another, are the most dangerous damage 
for a cell [22, 23]. These breaks can be caused by both 
exogenous and endogenous sources including reactive 
oxygen species, ionizing radiation [24], replication fork 
collapse [22, 25], or the faulty action of nuclear enzymes 
such as topoisomerase II [26, 27]. Regardless of origin, 
DSBs are fatal to the cell if not repaired. When faced with 
such a damage, the cell must repair the damage in order to 
survive or continue dividing [22]. Double strand breaks are 
repaired by one of two pathways in Eukaryotic cells [28]. 
During S and G2 phases of the cell cycle, when DNA has 
been replicated and exists in pairs of sister chromatids, the 
cell is able to fix the breaks with the high fidelity process of 
Homology Dependent Repair (HDR) [29, 30]. This process 
involves resection of one strand of a broken end to produce 
a single stranded overhang that can invade the helix of the 
sister chromatid. Polymerase then uses the sister chromatid 
to fill in sequence on the broken ends and the strands are 
resolved to separate, complete sister chromatids [26, 31]. 
During the rest of the cell cycle, or in non-dividing cells, 
no identical sequence template is available to allow HDR 
to proceed, so the cell turns to the faster but more error 
prone process of Non-Homologous End Joining (NHEJ) 
[32, 33]. This process proceeds through recognition and 
binding of the broken ends by Ku 70-80 proteins and 
DNA-PKcs [34]. Together, this complex has a role similar 
to that of Proliferating Cell Nuclear Antigen (PCNA) 
during replication as it acts as a docking platform for other 
proteins. During repair, these other proteins are nuclease, 
polymerase, and ligase complexes needed to process 
the repair. The DNA-PKcs complex with Artemis has 3’ 
and 5’ endonuclease as well as 5’ exonuclease activity, 
allowing it to process a diverse array of damaged DNA 
ends. Polymerases μ and λ are also able to interact with 
the complex, allowing flexible and template-independent 
synthesis. The processing of DNA ends during NHEJ is 
not fully understood and is not the same for each break; 
even identical breaks in the same location show variation in 
end processing [34]. Blunted DNA ends are subsequently 
ligated through the action of XLF:XRCC4:DNA ligase 
IV complex. Although the immediate threat to the cell is 
averted by repair of the DSB, repair by NHEJ often results 
in deletions or frame shifts in the repaired area as a result 
of end processing. This process is a major source of DNA 
mutation in arrested cells [35]. Despite its limitations, the 
quick kinetics and ability to repair without a template make 
NHEJ the repair pathway of choice in cells outside of S and 
G2 and in non-dividing cells. It is the predominant DSB 
repair pathway in animal cells since it occurs throughout 
the cell cycle [32, 33].
Studies of HDR have determined that, following 
repair, some cells exhibit robust expression of the repaired 
gene while others show low expression levels. It was 
determined that these expression classes arise as a result of 
epigenetic reprogramming, more specifically, altered CpG 
methylation at the repair site [36–38]. In addition, specific 
DNA methyltransferases have been found to localize at 
DNA repair sites [36]. During S phase, DNMT1 methylates 
hemimethylated DNA during replication, copying the 
methylation profile of the parental DNA strand to the 
daughter strand, a process which is also ongoing when 
DNA methylation is altered post-HDR [36, 39]. Thus, 
DNA methylation exists in a triad of dynamic, interworking 
processes along with DNA replication and HDR.
The mechanism for DNMT-mediated methylation at 
repair sites following NHEJ, which occurs independently 
of DNA replication, is less well understood despite being 
a prominent DNA repair pathway in animal cells. We 
address this topic in the current paper. Specifically, in this 
work, we report the following observations. First, NHEJ 
repair pathway attended by DNA methylation revision 
in somatic human cells. Second, specific methylation 
sites map on the repaired gene to sites that are distinctly 
different from those seen in the HDR pathway [36]. Third, 
we show that epigenetic revisions driven by NHEJ are 
stably inherited. In this work, we used a neutral gene 
to report alterations in DNA methylation to ensure that 
selective pressure post repair would not influence our 
ability to track the NHEJ descendants. Collectively, the 
data supports the notion that the prominent DNA repair 
pathway in animal cells is a source of genetic diversity but 
also a source of epigenetic (or gene expression) change in 
cases where a wild type allele is recovered post-NHEJ.
RESULTS
A neutral reporter system for analysis of 
epigenetic revision during NHEJ
In order to study the NHEJ repair pathway, we 
have generated a HeLa cell line containing a GFP based 
reporter construct [40, 41] (Figure 1A). The construct 
contains a CMV driven GFP gene that was interrupted by 
a rodent Pem1 intron. Within this intron, an adenoviral 
exon was added that is flanked by two restriction sites for 
the megaendonuclease, I-Sce1. There are no I-Sce1 sites 
in the human genome; Thus DSB are target to these twin 
sites. The presence of the viral exon disrupts the gene, and 
as a consequence, the cells are GFP negative; however 
when I-SceI is introduced to the cells, the adenoviral exon 
is excised by two DSBs and repaired by NHEJ. Since 
removal of the exon allows the construct to generate 
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WT GFP after splicing, cells have effectively undergone 
NHEJ repair and some sub-fraction of the cells will be 
GFP positive (since NHEJ is error prone, we cannot score 
mutant alleles with this assay based on GFP expression). 
In addition, there is no homologous DNA template for the 
repair event; therefore, this is a dedicated NHEJ repair 
process and HDR cannot proceed under these conditions. 
To improve accuracy and penetrance of the system, the 
gene for I-SceI gene has been placed in these HeLa cells 
under control of a Tet-On promoter, thus, the system is 
doxycycline inducible.
A segregation of expression classes following 
repair by NHEJ
The NHEJ reporter system was tested by adding 
Doxycycline (Dox) to the media of the IHN20.22 HeLa 
cells. We note that other clones tested behaved similarly; 
Figure 1: Doxycycline inducible construct uses GFP as a reporter for NHEJ. (A) Reporter construct integrated into the 
genome of the IHN20.22 HeLa cell line. The NHEJ reporter GFP gene contains a Pem1 intron interrupted by an adenoviral exon. Two 
I-Sce1 restriction sites allow the homing endonuclease to cut the DNA and excise the adenoviral exon to produce wild-type GFP following 
repair by NHEJ. (B) Generation of GFP positive cells following repair. Cells were induced with dox for 24 hours and then the percentage 
of the population expressing GFP was analyzed using FACS. The circles on the “+Dox” plot indicate two separate GFP positive cell 
populations with differing expression levels of GFP (C) Time course analysis. The percentage of GFP positive cells was analyzed by FACS 
over the course of 9 days, either following a 24-hour induction or with continuous exposure to doxycycline. The uncut cell line with no 
dox exposure was also analyzed to asses basal levels of GFP expression. (D) The onset of WT GFP expression in a single cell during the 72 
hours following a 24 hour Dox induction was observed using live-cell imaging. The arrows indicate time progression and the black circle 
indicates the GFP negative cell that is GFP positive in subsequent images.
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however some clones displayed higher backgrounds, 
probably due to leaky I-Sce1 expression in the absence of 
Dox. IHN20.22 was selected since this clone exhibited low 
levels of GFP positive cells in the absence of Dox. I-Sce1 
induction was quite robust in IHN20.22 cells and within 
a few hours after Dox addition, Western blots showed the 
presence of prominent amounts of I-Sce1 protein (data not 
shown). At 24 hours post-Dox, GFP expressing cells could 
readily be seen by live imaging or fluorescent microscopy. 
GFP levels could also be measured using flow cytometry 
(Figure 1B). The percentage of GFP positive cells 
steadily increases over time with continuous exposure 
to Doxycycline, while in negative controls (no Dox) the 
percentage of GFP positive cells stays well under 1% 
which we attribute to leakiness of the Tet-On promoter, 
as noted. After a 24 hour pulse with Dox, the percentage 
increases and then peaks at about 5-7% after four days 
(Figure 1C). The emergence of GFP positive cells can be 
observed via live imaging during the 72 hours following 
induction with Doxycycline (Figure 1D) as a GFP negative 
cell (circle, top image) undergoes NHEJ repair and begins 
to express WT GFP as time progresses to the second 
image. Since the post-repair cell now contains a WT GFP 
gene, division produces two GFP positive daughter cells 
in the last image. By limiting the expression of I-Sce1 
to 24 hours, the pulse-chase experimental schematic 
allows for focused investigation of the processes that 
occur following a DSB without the added variables of 
continuous DSB induction and continuous Dox treatment. 
Note that the scatter plots in Figure 1C appear to contain 
dual populations of GFP positive cells (dashed rings). 
The two populations, which appear to differ in total GFP 
expression levels were more clearly observable after Dox 
induction with I-Sce1; however in the negative controls, 
this heterogeneity was observed. This was examined in 
more detail in order to understand the underlying basis for 
this observation.
GFP Expression is heterogeneous in repaired cell 
populations following NHEJ
The histogram of GFP positive cells reveals the 
emergence of two expression classes with differing GFP 
intensities. One class expresses GFP robustly while 
the other maintains lower expression levels. We refer 
to these populations as Bright and Dim, respectively 
(Figure 2A). To determine if the differing expression 
classes may be a result of DNA methylation, we tested 
whether the expression classes were altered by the DNA 
hypomethylating drug, 5’-Aza-2’-Deoxycytidine (AzadC). 
This drug acts by inducing a stable, covalent complex 
between the methyl's and DNA [36, 42–44]. The result is 
hypomethylation of the genome due to the sequestering of 
DNMTs that are covalently bound to DNA. This prevents 
further methyltransferase action and effectively inhibits 
the overall DNA methylation of the cell. Based on this 
known mechanism, multiple cell divisions are required in 
order to observe genome-wide hypomethylation, which is 
manifested in the daughter cell population.
When IHN20.22 cells are induced with Dox and 
then treated with AzadC, there is an obvious shift of 
cells from the low expressing Dim population to the high 
expressing Bright population (Figure 2B). The conversion 
of ‘dim’ cells to ‘bright’ cells by the hypomethylating drug 
suggests that the repaired GFP gene in the low expressing 
pool is a direct result of DNA methylation either during 
or soon after NHEJ repair. In the absence of AzadC, the 
Bright population of cells initially decreases over 4 days 
then appears to stabilize (Figure 2C, -AzadC). In contrast, 
cells treated with AzadC displayed a clearly different 
trend (Figure 2C, -AzadC). The drug reverses the loss in 
Bright cells, probably due to the ongoing conversion of 
Dim cells into the Bright pool. In either case, a few days 
after the damage/repair event, the proportions of cells 
in Bright and Dim cell populations remain fairly stable 
as cells are passaged (Figure 2C); however, addition of 
AzadC to cells that are 24 days post-repair results in a 
sharp increase in the percentage of high expressing cells 
(Figure 2D), supporting the notion that the expression 
difference is likely due to post-repair methylation as 
opposed to an off target drug interaction during the repair 
process. Further, the extent to which AzadC causes the 
shift from low to high GFP expression occurs is dose 
dependent (Figure 2E).
Since it appears that the expression classes 
eventually become stable, presumably due to stable 
methylation marks (which are heritable) we next attempted 
to isolate pure populations of Dim and Bright cells to 
make the analysis more tractable. Before treatment, sorted 
Dim cells appear as a relatively homogenous population 
in a uni-modal distribution (Figure 3A) with relatively 
low levels of GFP expression (labeled as the “P1” pool). 
Note that while the distribution is broad, it is nonetheless 
uniform with very low levels of bright GFP expressing 
cells (P4). Following AzadC treatment of the Dim cell 
pool, a new population emerges in the high expression 
range (Figure 3A right panel “P4” pool). As with sorted 
Dim cells, sorted Bright cells also show a single peak of 
GFP expression (Figure 3B); however these cells are far 
more homogeneous (compare 3A, B). Since the Bright 
cell pool also shifts perceptibly to the right in the presence 
of AzadC (Figure 3B, right panel, P4), we conclude that 
the bright pool contains cells with some degree of DNA 
methylation (which is removed by AzadC) (Figure 3B). 
This experiment clearly evidenced the conversion of Dim 
cells to Bright cells by a DNA hypomethylating drug. 
Live imaging reveals that the information regulating the 
GFP expression level of post-repair cells is passed from 
parent to daughter cells as the cells divide (Figure 3C, 
Supplementary Movie 1). The cause of the silencing 
is heritable but reversible, pointing once more to DNA 
methylation as the source of the gene expression variation.
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Figure 2: The effect of induced hypomethylation on the distribution of cells in Bright and Dim GFP expression classes. (A) 
Histogram of GFP+ cells after induction with dox with gating for Bright and Dim populations. (B) Hypomethylation by 5’Aza-2’-deoxycitidine. 
IHN20.22 cells were induced with dox for 24 hours and then treated with a daily dose of 1μM AzadC for 48 hours. The percentage of cells 
with high (Bright) and low (Dim) GFP expression with and without AzadC treatment were quantified using FACS histograms of GFP positive 
cells. The second graph is an overlay of the histogram with (red) and without (blue) treatment with AzadC. (C) Characterization of the effect of 
hypomethylation by AzadC on the GFP expression level in post-repair cells. The first graph compares the GFP expression level over the course of 
7 days with and without AzadC treatment. Cells were induced with dox for 24 hours and then given a daily dose of 1μM AzadC. The percentage 
of Bright cells was measured using FACS on days 1, 2, 4 and 7 following initiation of AzadC treatments. (D) The distribution of cells in each 
expression class was observed in the days following NHEJ repair. As indicated by the arrow on the last graph, the cells were treated with 5μM 
AzadC on day 25 and then analyzed by FACS on day 26, 27, 28, and 30. (E) Comparison of the effect of AzadC at different concentrations. Cells 
were induced with dox for 24 hours and then given a daily dose of the indicated concentration of AzadC for 2 days. After a 48-hour recovery, the 
percentage of Bright cells was determined using FACS. The fold increase in the percentage of bright cells is shown.
Figure 3: (A, B) Dim (A) and Bright (B) populations were sorted using FACS and then the sorted populations were 
treated with a daily dose of AzadC for 48 hours. The level of GFP expression was measured using FACS. The blue line in (B) 
indicates the median of the Bright peak. (C) Live cell imaging was used to observe the origination and propagation of cells with Dim and 
Bright expression of GFP during the 72 hours following a 24 hour dox induction. The arrow indicates the progression of time
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The availability of relatively pure populations of 
Dim and Bright cells makes it possible to use bisulfite 
DNA sequencing to interrogate methylation sites before 
and after NHEJ. Thus, in addition to validating the 
presence of epi-alleles in Dims and Brights, bisulfite 
DNA sequencing of the post-repair populations makes 
it possible to map these epi-alleles relative to the I-Sce1 
cleavage and repair site. Bisulfite sequencing confirmed 
that the GFP gene is hypomethylated in sorted Bright cells 
and hypermethylated in sorted Dim cells. Specifically, 
changes occur in regions both up and downstream of the 
break site (Figure 4). Interestingly, the methylation status 
of CpGs in the region directly flanking the break site is 
not affected by the process. This suggests a coordination 
of methylation and repair proteins to affect methylation 
patterns in specific areas around the site of DNA damage.
Different DNA methylation patterns mark 
RECOMBINANT from UNCUT cells
The data so far demonstrate that NHEJ is spinning 
out new epi-alleles that are either over-written or 
completely revised from the parental (uncut) reporter 
DNA. Moreover, the expressability of the repair products 
correlates with the percent of DNA methylation in sorted 
Dim and Bright cells. The pyrosequencing analysis 
done thus far evaluates the average methylation levels 
for a single CpG site derived from physically different 
molecules; however it does not consider the relationship 
between the different methylated cytosines present on 
the same molecule (epialleles). For this reason, we have 
analyzed the composition of methylated population 
(heterogeneity), by counting the number of different 
epialleles in the sample (haplotypes) obtained from deep 
sequencing analysis of the amplicons.
The DSB region was divided into 5 segments (3 
upstream and 2 downstream regions from the DSB site, 
see top diagram in Figure 5). Deep quantitative (Taxa, 
PCoA and Shannon Index) and qualitative (methylation 
profiles) analysis of amplicons with the same end was 
carried out. The results show that recombinant cells (both 
Dims and Brights) and uncut parental cells have the 
same types of methylated species (un-methylated, mono, 
bi and tri-methylated) but with different compositions 
(Figure 5A, Supplementary Table 1). In fact, the Bright 
cells appear to be rich in unmethylated species compared 
to Dims and Uncut in each region, confirming that high 
levels of GFP expression in this population are largely 
unmethylated (marked by an asterisk in Figure 5A). 
Moreover, Principal Coordinates Analysis reveals that 
Dim and Uncut parental DNAs have a smaller euclidean 
distance compared to Bright (variation 96% vs 4%), 
highlighting a common origin for Recombinant (ie, NHEJ 
repaired) cells, followed by a de-methylation event of the 
Bright cells (Figure 5B). We also analyzed the diversity 
index (Shannon Index) in order to evaluate the evenness 
Figure 4: Bisulfite Sequencing of sorted Dim and Bright cells. Next-Generation Sequencing of bisulfite converted DNA was 
used to determine the methylation patterns of the area around the site of repair in sorted Dim and Bright cell populations as well as uncut 
IHN20.22 cells
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of the species. Except for the region 1 (where Bright and 
Uncut are much more similar to the Dims), we observe 
that 2 upstream regions of DSB site (Region 2 - 3) show 
a gradual increase in similarity between Dims and Uncut 
relative to the Bright cells (single asterisk*), while region 
4 (downstream region of DSB site) shows a high similarity 
between the Recombinants (Dims plus Brights) compared 
to the Uncut (double asterisk **), which is lost in the 
region 5 (Figure 6A).
Finally, we have performed a deep qualitative 
analysis to identify the differences between Recombinant 
and Uncut (parental) cells in terms of gain or loss of 
methylation. The differences between the percentage of 
Recombinant’s epialleles compared to Uncut cells show 
that the Dim cells gain methylation marks in the region 
1 (di-methylated epialleles), in the region 2 (mono-, di- 
and tri-methylated epialleles), and in the region 5 (mono-, 
di- and tri-methylated epialleles). In contrast the Bright 
cells lose methylated epialleles in these same regions. For 
example, in region 3, Bright cells appear to acquire new 
methylation (di-methylated epialleles) while DIMS lose 
methylation. Both Dims and Bright cells lose methylation 
(tri-, di-methylated epialleles) acquiring mono-methylated 
epialleles in the region 4. Knowing the different GFP 
expression between the two populations, we hypothesize 
that transcription may modify DNA methylation (or 
de-methylation) after DNA damage and NHEJ repair, 
remodeling the chromatin in units with different 
transcriptional efficiency (and in the process spinning out 
Dim and Bright cell populations) [38].
DISCUSSION
Epigenetic revision as a component of 
tumorigenesis
This study reveals a novel connection between two 
essential cellular processes that has a potential role in the 
development and progression of cancer. Cancerous cells 
arise in a multi-step process as a result of an upset in the 
balance of oncogenes and tumor suppressor genes that 
causes deregulation of normal epistasis. This imbalance 
may derive from genetic mutations that affect this balance; 
however changes in expression levels can also be caused 
by inappropriate DNA methylation marks. Moreover, the 
addition or removal of post-translational modifications 
to histones can affect the access of transcriptional 
machinery to particular genes by opening or closing 
the chromatin, causing gene activation or repression, 
respectively [11, 19, 45, 46]. Both hypermethylation and 
hypomethylation can contribute to tumorigenesis when 
they occur at inappropriate positions in the genome. DNA 
Figure 5: Qualitative DNA methylation profiles discriminate BRIGHT molecules from DIMS and UNCUT molecules. 
Epialleles profiles obtained from the analysis of the methylation of each amplicons were subjected to alpha and beta diversity (Qiime). (A) 
Profile composition of relative sample (BRIGHT, DIMS and UNCUT) grouped by number of methylated CpGs for the five regions adjacent 
to the DSB. “0 (red color = un-methylated)”, “1 (blue = mono-methylated)”, “2 (orange = di-methylated)” and “3 (green = tri-methylated)” 
represent the percent to class of methylation. (B) Principal coordinate analysis of BRIGHT, DIMS and UNCUT. In the X and Y axes are 
represented, respectively, the first and the second components (PC1 and PC2) with the amount of variance in the samples explained by these 
components, included in brackets. The first principle component represents the highest variance, and the total variance of the samples is the 
cumulative sum of that described by each of the axes.
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hypermethylation is generally associated with gene silencing 
while hypomethylated is associated with gene activation 
[19, 20]. Changes in the cellular DNA methylome resulting 
in hypermethylation of tumor suppressor genes including 
APC, BRCA1, E-cadherins, DAPK1, hMLH1, p15, Rb, 
MGMT, and p16INK4a have been documented in tumors 
from a variety of cancers including breast, colon, gastric, 
ovarian, lung, brain, ovarian, renal, kidney, prostate, 
thyroid, lymphoma, and leukemia [11, 19, 20]. In addition 
to silencing tumor suppressor genes, hypermethylation 
can cause down regulation of miRNAs, some of which 
have tumor suppressing activity [47–49]. For example, 
miR124a is frequently down regulated in several cancer 
types including colon, breast, and lung carcinomas as well 
as some leukemias and lymphomas. Because this miRNA is 
a negative regulator of CDK6, down regulation caused by 
hypermethylation results in increased levels of CDK6 which 
in turn facilitates inactivation of RB1 via phosphorylation 
[50] Since miRNAs have also been shown to regulate 
epigenetic processes through interaction with DNMTs 
and EZH2 complexes [51, 52], downregulation could 
potentially propagate DNA methylation changes in other 
areas of the genome. Hypomethylation has also been shown 
to contribute to tumorigenesis by over-activating oncogenes 
and contributing to genetic instability and structural changes 
by promoting an open chromatin state [20, 53].
Cancer cells coordinate genetic mutations and 
epigenetic revision in order to promote carcinogenesis. 
According to the two-hit hypothesis, a tumor suppressor 
gene must be deactivated in both alleles in order to cause 
cancer. HCT116 colon cancer cells were found to have 
genetic mutations in one allele of both CDKN2a and 
MLH1 and epigenetic silencing of the second allele, 
demonstrating the collaboration of genetic mutation and 
hypermethylation in achieving the second ‘hit’ to cause 
loss of heterozygosity and inactivation a tumor suppressor 
gene [20]. Both hypermethylation and hypomethylation 
can also contribute to cancer progression by promoting 
mutagenic processes. This is observed in the silencing 
of genes involved in DNA repair via hypermethylation, 
which results in defective repair pathways and increased 
DNA mutagenesis [45, 54]. In addition, hypomethylation 
can cause over expression of an oncogene due to the 
loss of genomic imprinting that results in the expression 
of both alleles instead of only one allele [55, 56], and 
hypomethylation of LINE retrotransposons facilitates 
insertion mutagenesis [57, 58].
Despite their involvement in so many types of 
cancer, the root cause of DNA miscues is largely unknown. 
Deep sequencing analysis of post-repair DNA revealed 
both loss and of methylation in areas up and downstream 
of the break site (Figure 6B) that is correlated with up- or 
downregulation, respectively. The mechanism described 
here provides evidence for alterations in methylation 
profiles as a result of NHEJ repair, a process which could 
explain the epigenetic revision that is characteristic of 
Figure 6: Regions adjacent to DSB give discriminate REC from UNCUT and BRIGHT from DIMS. Epiallelesprofiles 
obtained from the analysis of the methylation of each amplicons were subjected to alpha and beta diversity (Qiime). (A) Shannon diversity 
index between BRIGHT, DIMS and UNCUT. In the X and Y axes are represented, respectively, “number of sequences for sample” and 
“Rarefaction measure (species richness)” for Shannon Index. (B) Gain or loss of methylation in BRIGHT and DIMS compared to the UNCUT.
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cancer cells. What is not clear is how universal and wide-
spread NHEJ-mediated epigenetic revision paths are in a 
tissue context. In our model system, we used a gene that 
is not subject to selection; however it stands to reason 
that silencing or activating a positive or negative growth-
promoting gene could produce cells that have a growth 
advantage relative to surrounding normal cells [11, 20, 
59]. Growth promoting outcomes could clearly place 
the cell on a path toward a pre-cancerous condition. In 
contrast, silencing a pro-growth gene (oncogene) could 
result in the loss of a cell lineage. In either situation, tissue 
epistasis could be targeted with undesirable outcomes. 
What is intriguing is that even when an error-prone 
pathway such as NHEJ regenerates wild-type sequence, 
there is still a good chance for gene activation or silencing. 
Thus, mutating a tumor suppressor gene is functionally 
equivalent to epigenetic silencing the expression of the 
same gene, with the same dire consequences.
A new pathway for discovery of novel epi-
therapeutic targets
Changes in DNA methylation have been shown to 
accumulate throughout the genome with the progression of 
cancer [59–62] and have been shown to positively correlate 
with tumor stage [61]. Cancer cells have also been shown 
to acquire additional genetic mutations due to an increase 
in DSBs resulting from increase reactive oxygen species 
production, telomeric dysfunction, genomic instability, 
and replication errors [33, 63]. Although the increased 
DSB may give cancer cells a growth advantage by 
providing favorable mutations in key regulatory genes, it 
also makes them increasingly dependent on DSB repair 
in order to grow and proliferate at a high rate. If DNA 
methylation revisions occur during or soon after NHEJ, 
as demonstrated here, further DSB repair that occurs in 
rapidly dividing cancer cells may exacerbate the situation 
and could explain the accumulation of inappropriately 
methylated or demethylated genes that is characteristic of 
progressing cancer.
One important property of epigenetic alterations 
that makes them an idea therapeutic target is that they are 
reversible. This is in contrast to genetic mutations that are 
embedded in the DNA sequence. In fact, hypomethylating 
drugs including 5’Aza-2’-deoxycitidine (Decitabine), and 
1-β-D-ribofuranosyl-2(1H)-pyrimidinone (Zebularine), 
have been shown to have positive effects when used to 
treated cancer cells. The FDA has approved the use of 
Decitabine for treating myelodysplastic syndrome and 
Zebularine for treating hematological malignancies 
[19, 46, 56, 62]. Studies have also shown that antisense 
and small interfering RNA (siRNA) targeting DNA 
methyltransferase mRNA can inhibit growth of colon 
and renal cell carcinoma cells [46, 56]. The association 
of methylation revisions with tumor stage could enable 
their use as a cancer marker to predict prognosis of 
developing cancer and to predict responsiveness to 
specific therapeutics [56]. Further, although methylation 
aberrations tend to accumulate with malignant 
progression, they have also been shown to be present in 
the early stages of pre-malignancy [20, 62, 64]. This could 
make them candidates for use as a diagnostic tool for early 
detection of cancer cells [62, 64]. Further, exposing the 
mechanism behind the overlap of these key processes 
could provide new targets for therapeutics to interfere 
with the progressive gain of epigenetic miscues by this 
mechanism and prevent tumor progression.
Intragenic DNA methylation and gene silencing
While methylation based gene silencing is typically 
associated with promotor CpG islands, studies have 
also shown that intragenic methylation may affect gene 
expression as well. Intragenic methylation in plant cells 
was shown to increase in more highly transcribed genes, 
presumably in an effort to prevent aberrant transcription 
at other nearby sites that can result when transcription 
machinery disrupts chromatin structure. Inhibition of DNA 
methylation in these cells caused up regulation of genes 
that were methylated only in the body of the gene and 
not in their promoters [65]. Similar results were found in 
mammalian cells where intragenic methylation was shown 
to decrease gene expression and facilitate compaction of 
chromatin that is correlated with a reduced density of 
DNA polymerase II in the body of the gene [66]. Further, 
another study concluded that a single methylated CpG in 
the intron of the PMP24 gene was sufficient to silence the 
gene. In addition to demonstrating the ability of intragenic 
methylation to silence genes, these studies suggests a 
connection between methylation and reduced elongation 
efficiency. This supports our findings that aberrant 
methylation in the body of the GFP gene causes silencing.
This also incites the idea that transcription may 
reshape the epigenetic landscape, a phenomenon that has 
already been demonstrated to occur following DNA repair 
by HDR [37]. It was found that this process is mediated 
by Base Excision Repair (BER)-mediated demethylation 
[38]. Principle Coordinates Analysis presented in Figure 
5B revealed that Dim cells had a closer Euclidian distance 
to the original, uncut parental DNA than Bright cells. This 
data supports a model where the area surrounding the 
site of NHEJ is first methylated and then progressively 
demethylated over time with transcription, resulting in an 
array of epialleles with differing levels and locations of 
methylated CpGs. Future work will look further into this 
idea.
In summary, this study reveals a novel connection 
between two processes that have important roles in 
cancer development and progression, NHEJ and DNA 
methylation. This link provides a clue to one of the biggest 
unanswered question in this area of study: What causes 
the epigenetic revision that is pivotal to the multistep 
progression of cancer? While DNA damage and repair 
is stochastic, a damage event that results in epigenetic 
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revision following repair and provides the cell with 
a growth advantage could direct the cell onto a path of 
tumorigenesis. This could explain why some genes exhibit 
inappropriate methylation patterns in some cancers but not 
others, as only genes that are beneficial to that particular 
tissue type would confer a selective advantage. Thus, 
methylation revision following DNA repair by NHEJ, 
the most predominant repair pathway in animal cells, fits 
the criterion to be the source of epigenetic abnormalities 
in cancer cells and could provide information for 
the development of new therapeutic strategies for 
preventing and stopping this process from contributing to 
tumorigenesis.
MATERIALS AND METHODS
Cell culture
The stable HeLa cell line was cultured in RPMI 
medium with L-glutamine and supplemented with 10% 
fetal bovine serum and 1% penicillin-streptomycin. Cells 
were grown in at 37°C at 5% CO2.
Stable cell line
HeLa cells were transfected with a Tet-On inducible 
gene expression system (Clontech) and set to target the 
I-Sce1 gene according to the Tet-On system manual. After 
generation of a stable Tet-On cell line, the cells were 
transfected with the GFP reporter construct for NHEJ 
provided by the Gorbunova lab [40]. These cells were 
grown under selective pressure with Geneticin (G418) 
to generate the stable iHN20.22 cell line containing the 
reporter construct and a tetracycline inducible I-Sce1 gene.
Tet on promoter activation
iHN20.22 cells were treated with 1μg/mL 
doxycycline for varying durations to determine the optimal 
induction time. It was determined that a 24 hour pulse of 
doxycycline was sufficient to induce the NHEJ system, so 
this was used in future experiments.
FACS analysis
IHN20.22 cells were trypsinized and centrifuged at 
1000xg for 5 minutes and then and resuspended in PBS at 
a density of 106 cells/mL. Live cells were selected using 
a plot of SSC-A vs. FSC-A, and GFP positive cells were 
identified using a plot of FSC-A vs FL1A-A. The FL1-A 
histogram was then used to identify and gate the distinct 
populations of low and high expressing cells.
Live cell imaging
Cells were seeded at low density in glass bottom 
culture dishes (MatTek) induced with Dox for 24 hours 
and then placed into an incubation chamber that is part of 
a Perkin Elmer UltraVIEW VoX 3D Live Cell Imaging 
System attached to a Zeiss Axio Observer Z1 inverted 
fluorescence microscope. Images were taken every 5 
minutes for the next 48 hours and then analyzed using 
Volocity Imaging and Analysis software (Perkin Elmer).
Drug treatments
IHN20.22 cells were plated at low confluence and 
induced with doxycycline for 24 hours. After 24 hours, 
media was removed and replaced with fresh media and 
cells were given a daily dose of 1μM 5-AzadC or 1% 
DMSO control for 48 hours (unless otherwise noted) and 
then were harvested for FACS analysis.
Cell sorting
Dox induced IHN 20.22 cells were treated with 
dox for 24 hours and then grown under normal culture 
conditions until the GFP expression levels stabilized. 
Cells were then harvested and resuspended in median 
containing RPMI, 1% penicillin-streptomycin, 20mM 
Hepes buffer, and 2% FBS at a density of 3x106 cells/
mL. Cells were run through FACSAria flowcytometer and 
sorted by using the FSC-A and FITC-A plot to gate GFP 
positive cells and then using the histogram of FITC-A 
to select ‘dim’ and ‘bright’ populations. Two sorted 
populations (Bright and Dim) were collected in a tube 
containing media supplemented with 30% FBS and then 
transferred to culture dishes containing culture medium 
(RPMI supplemented with 10% FBS and 1% Penicillin-
streptomycin) at 37°C at 5% CO2.
Bisulfite converted DNA preparation
Genomic DNA was extracted from iHN20.22 
cells (uncut) as well as the sorted bright and dim 
populations using Wizard genomic DNA purification 
kit” (Promega). 100ng of extracted DNA was used for 
bisulfite conversion using the Epijet Bisulfite Conversion 
Kit (Thermoscientific). Regions on either side of the repair 
site in bisulfite converted DNA were amplified using 
Phusion U Hot Start Polymerase (Thermoscientific) and 
the following 5 sets of primers (NHEJ1-5): NHEJ1-F, 
5’-GTGATTATGGTTTTGTTTTTTTTTTTGGAATTGT 
-3’; NHEJ1-R, 5’-CTAACACTCCCTACTTAATAAAAA
CTCC-3’; NHEJ2-F, 5’-GGAGTTTTTATTAAGTAGGG
AGTGTTAG-3’; NHEJ2-R, 5’-CCCCATAAAAACCCA
CAATATTTCAAATC-3’; NHEJ3-F,; 5’-AGGTTAGTTT
GGGTTATATGAGAGTTTG-3’; NHEJ3-R, 5’-TTTCA
AACTACCCCATATAACATCTAACC-3’; NHEJ4-F, 5’
-TGGTAAGGGATTTTGTAGATTATTGGATTTAG-3’; 
NHEJ4-R, 5’-CTACTATACTCACCCATTATTCTAAAA
ACAC-3’; NHEJ5-F 5’-AGGTTGTATTTTATTTTTATAG
TTAGGTTTGTTTAGG-3’; NHEJ5-R 5’-ATCTAAAAAT
ACATTAAAAAATCCTCTTTCCCCTTC-3’; The 5 PCR 
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fragments of each sample (uncut, sorted Dim, and sorted 
Bright) were purified using GENEjet PCR purification kit 
(Thermoscientific).
Bisulfite sequencing
These samples were transferred to the core sequencing 
facility at Sanford Burnham at Lake Nona, Orlando Florida. 
Illumina’s Truseq ChIP Library Preparation kit was used 
to prepare a total of 15 libraries (5 fragments each for 3 
samples: uncut, sorted Dim, and sorted Bright) from 
10ng of input DNA. Quality and quantity of the libraries 
were analyzed using an Agilent Bioanalyzer and Kapa 
Biosystems qPCR. The Multiplexed libraries were pooled 
and subjected to Paired-end 2x250-bp sequencing using one 
flow-cell of a Miseq sequencing instrument.
Methylation analysis
FastQ files were subjected to quality check using 
FASTQC software ( https://www.bioinformatics.babraham.
ac.uk/projects/fastqc/). Then, paired-end reads from the 
sequencer platform were merged together using PEAR 
tool [67] with a minimum of 40 overlapping residues as 
threshold (mean PHREAD score of at least 33) and merged 
FastQ files were converted in Fasta using Prinseq. [68] To 
analyze the methylation status of each amplicon, we used 
AMPLIMETHPROFILER [69] specifically designed for 
deep targeted bisulfite amplicon sequencing of multiple 
genomic regions. This pipeline is freely available at 
https://sourceforge.net/projects/amplimethprofiler and is 
organized as follows: first, it recognizes corresponding 
target region discarding PCR artifacts and reads that do 
not match expected lengths; then, reads are aligned to the 
corresponding bisulfite-converted reference using BLASTn 
[70]. We used very stringent parameters: fragment 
length threshold, 50%; threshold alignment primers, 
80%; bisulfite conversion efficiency, 99% and threshold 
alignment to reference, 50%. The pipeline output format 
reports the methylation status for each CpG dinucleotide 
coded 0 as non-methylated, 1 as methylated, and 2 if the 
methylation state cannot be assessed. We use this output to 
perform the analysis. Quantitative methylation average for 
each site is represented by the ratio between the number 
of non-converted bases at that site and the total number 
of mapped reads. The abundance of each of the 2NCpG 
distinct epialleles (where NCpG stands for the number of 
CpG sites in the analyzed region) was evaluated for each 
sample by counting the number of passing filter reads 
containing that epiallele. Qualitative methylation analysis 
was performed using Qiime [71], which includes: 1. a 
“summary”, the number of profiles present in each input 
sample; 2. a “taxa_summary_plots”, the information on 
the distribution of methylation profile classes; 3. “alpha 
diversity”, the five alpha diversity metrics for each sample: 
a. number of different methylation profiles in the sample; 
b. shannon entropy; c. simpson index; d. Chao 1 index ; 
e. number of singletons. Such metrics were computed 
through a rarefaction procedure to take into account 
biases derived from variable sequencing depth and; 4. 
“beta Diversity”, the distance between samples in terms 
of composition of their methylation profiles, measured by 
Bray–Curtis dissimilarity: 5. PCoA Principal Coordinates 
analysis.
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